허가-특허 연계제도 법률안의 검토
Korea’s Patent Linkage Bill and Its Analysis
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
The Korea-US Free Trade Agreement stipulates that Korea should adopt patent-registration linkage by March of 2015. The patent listing (Green List), marketing prevention and generic exclusivity mechanisms recently proposed in a bill by the Korean government all have shortcomings. This article explores those shortcomings and possible fixes. The bill also should have established mechanisms through which a pioneer drug company will compensate for undue delay it causes in the marketing of a generic drug. In addition, the special appeals commission envisioned in the bill is not justified based on the nature of the actions to be taken by the Korean drug regulator under the bill. The bill appears to have largely been modeled after the Hatch-Waxman Act. In light of the differences in the legal institutions and health care market between Korea and the U.S., Korea’s patent linkage implementation should look at other examples, such as Canada and Australia, and will eventually have to stand on its own.
Abstract
The Korea-US Free Trade Agreement stipulates that Korea should adopt patent-registration linkage by March of 2015. The patent listing (Green List), marketing prevention and generic exclusivity mechanisms recently proposed in a bill by the Korean government all have shortcomings. This article explores those shortcomings and possible fixes. The bill also should have established mechanisms through which a pioneer drug company will compensate for undue delay it causes in the marketing of a generic drug. In addition, the special appeals commission envisioned in the bill is not justified based on the nature of the actions to be taken by the Korean drug regulator under the bill. The bill appears to have largely been modeled after the Hatch-Waxman Act. In light of the differences in the legal institutions and health care market between Korea and the U.S., Korea’s patent linkage implementation should look at other examples, such as Canada and Australia, and will eventually have to stand on its own.
참고문헌 (45)
- 의약품분야 지적재산권 관련 경쟁제한행위에 대한 외국사례분석 및 효과적인 법집행 방안 연구, "공정거래위원회", ~ (2009)
- 권남훈, "역지불합의의 경쟁제한성 판단", 산업조직연구, 21(1), pp.59~94 (2013), 한국산업조직학회
- 권오희, "특허법원 개원 10주년 기념논문집" (2008), 특허법원
- 권혜영, "제네릭 진입이 약품비에 미치는 영향 분석", 보건경제와 정책연구, 17(4), pp.23~42 (2011), 한국보건경제정책학회
- 김대중, "의약품 허가특허연계에서 제네릭 시장독점제도에 관한 연구", 보건경제와 정책연구, 19(1), pp.55~75 (2013), 한국보건경제정책학회
- 김현수, "역지급 합의의 규제에 관한 연구", 비교사법, 18(3), pp.915~948 (2011), 한국비교사법학회
- 김호철, "韓美自由貿易協定 醫藥品 知財權 協商結果 關聯 法的 爭點 分析", 서울대학교 법학, 50(2), pp.615~652 (2009), 법학연구소
- 민일영, "주석 민사집행법" (2012), 한국사법행정학회
- 한미 FTA 협상과 의약품 관리제도의 발전적 개선방안, "박실비아", 한국보건사회연구원, ~ (2007)
- 식품의약품안전처, "의약품 허가·특허 연계제도 세부운영요령", ~ (2012)
- 신혜은, "우리나라 제약산업 실정에 부합하는 한국형 허가-특허연계제도의 시행방안", 안암법학, (43), pp.1083~1118 (2014), 안암법학회
- 외교통상부, "한·미 FTA 상세설명자료", ~ (2011)
- 이숙연, "권리범위확인심판을 중심으로 본 특허 침해쟁송제도와 그 개선방안에 대한 고찰", 법조, 59(4), pp.98~150 (2010), 법조협회
- 이철남, "세계화시대의 기업법" (2010), 박영사
- 전효숙, "지식재산권의 행사와 부당이득", 법학논집, 16(2), pp.193~225 (2011), 법학연구소
- 정상조, "특허법 주해" (2010), 博英社
- 정윤택, "제약분야의 에버그리닝(Evergreening)특허전략과 FTA 연구", 지식재산연구, 6(2), pp.147~189 (2011), 한국지식재산연구원
- 정윤택, "제약분야의 특허분쟁사례를 통한 LCM과 에버그리닝의 이론과 논고", 기술혁신연구, 20(2), pp.135~160 (2012), 기술경영경제학회
- 정차호, "식약청 판매허가와 특허권의 연계를 위한 특허심판의 당사자 적격", 산업재산권, (25), pp.161~202 (2008), 한국지식재산학회
- 정차호, "한국형 허가-특허 연계제도에서의 제네릭 독점권 부여 여부", 과학기술과 법, 3(1) (2012)
- 식품의약품안전청, "성공적인 신약개발 제품화를 위한 길라잡이" (2012)
- 최성준, "權利範圍確因審判의 廢止의 妥當性에 관하여", 법조, 43(10) (1994)
- 최승재, "제약시장에서의 역지급합의에 대한 경쟁법 적용에 관한 연구", 경쟁법연구, 19, pp.118~158 (2009), 한국경쟁법학회
- 제약분야의 에버그린 특허전략과 분쟁 사례 연구, "한국보건산업진흥원", ~ (2009)
- 홍동표, "특허소송 합의에 대한 경쟁법 적용: reverse payment를 중심으로", 법경제학연구, 6(2), pp.183~198 (2009), 한국법경제학회
- Areeda, P., "Antitrust Law: An Analysis of Antitrust Principles and Their Application" (2012), Wolters Kluwer Law & Business
- Review of Pharmaceutical Patents in Australia, "Australian Government", ~ (2013)
- Avery, M., "Continuing Abuse of the Hatch-Waxman Act by Pharmaceu- tical Patent Holders and the Failure of the 2003 Amendments", Hastings Law Journal, 60 (2008)
- Bhardwaj, R., "The Impact of Patent Linkage on Marketing of Generic Drugs", Journal of Intellectual Property Rights, 18 (2013)
- Chisum, D.S., "Chisum on Patents: A Treatise on the Law of Patentability, Validity, and Infringement" (2012), Matthew Bender
- Crowne, E.A., "Innovators and Generics: Proposals for Balancing Pharmaceutical Patent Protection and Public Access to Cheaper Medicines in Canada (Or, Don’t NOC the Players, Hate the Regulations)", IDEA: The Intellectual Property Law Review, 51 (2011)
- Engelberg, A.B., "Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness?", IDEA: The Journal of Law and Technology, 39(3) (1999)
- Faunce, T., "Impact of the Australia―US Free Trade Agreement on Australian Medicines Regulation and Prices", Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 7(1) (2010)
- Generic Drug Entry Prior to Patent Expiration: An FTC Study, "Federal Trade Commission", ~ (2002)
- Federal Trade Commission, "Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2012", ~ (2013)
- Hemphill, C.S., "When Do Generics Challenge Drug Patents?", Journal of Empirical Legal Studies, 8(4) (2011)
- Ho, C., "Access to Medicine in the Global Economy: International Agreements on Patents and Related Rights" (2011), Oxford University Press
- Levin, R.C., "Appropriating the Returns from Industrial Research and Development", Brookings Papers on Economic Activity, 1987(3) (1987)
- Liu, B.P., "Fighting Poison with Poison-The Chinese Experience with Pharmaceutical Patent Linkage", The John Marshall Review of Intellectual Property Law, 11 (2011)
- Lopert, R., "The High Price of “Free” Trade: U.S. Trade Agreements and Access to Medicines", The Journal of Law, Medicine & Ethics, 41(1) (2013)
- Mansfield, E., "Patents and Innovation: An Empirical Study", Management Science, 32(2) (1986)
- Mossinghoff, G.J., "Overview of the Hatch-Waxman Act and Its Impact on the Drug Development Process", Food and Drug Law Journal, 54 (1999)
- Schacgt, W.H., "The “Hatch-Waxman” Act: Selected Patent- Related Issues" (2002), Congressional Research Service
- Thomas, J.R., "Patent “Evergreening”: Issues in Innovation and Competition" (2009), Congressional Research Service
- Thomas, J.R., "Pharmaceutical Patent Law" (2010), Bureau of National Affairs